France cancels order for Merck's COVID-19 antiviral drug

Reuters2021-12-22

PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck & Co's COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

windz123
2021-12-23
windz123
ok
kamy
2021-12-23
kamy
Gg
NeedMoneyPls
2021-12-22
NeedMoneyPls
Wow I thought they said it's much more effective than Pfizer and Moderna. Wonder issit they got paid off so the other two can continue to earn money.
- 慢的老人:
  I don't think any amount of money would be worth the reputational damage Merck would incur. It is more likely that Merck's drug was not tested extensively enough until now.
- halforc:
  ok
BillyWu
2021-12-22
BillyWu
Omg
StansenSG
2021-12-22
StansenSG
L
- StansenSG:
  L
Lollmaorofl
2021-12-22
Lollmaorofl
Ah shit definitely not the best news for Merck...

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2193019234?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-12-22 22:04","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2193019234","market":"us","top_or_hot":-1,"title":"France cancels order for Merck's COVID-19 antiviral drug","media":"Reuters","content":"<div>\n<p>PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck & Co's COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-france-cancels-order-mercks-135238223.html\">网页链接</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>France cancels order for Merck's COVID-19 antiviral drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFrance cancels order for Merck's COVID-19 antiviral drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-22 22:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/1-france-cancels-order-mercks-135238223.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck & Co's COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-france-cancels-order-mercks-135238223.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4550","symbol_name":"红杉资本持仓","start_time":0,"source_url":"https://finance.yahoo.com/news/1-france-cancels-order-mercks-135238223.html","article_id":"2193019234","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2193019234","pubTimestamp":1640181878,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck & Co's COVID-19 antiviral drug fo","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4550":"红杉资本持仓","MRK":"默沙东","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4516":"特朗普概念","PFE":"辉瑞","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓"},"translate_title":"法国取消对默沙东新冠病毒抗病毒药物的订单","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":0.9,"PFE":0.9},"content_text":"PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck & Co's COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end of January, the health minister said on Wednesday.\nFrance is the first country to publicly say it has cancelled an order for the Merck treatment after the company released data in late November suggesting its drug was markedly less effective than previously thought, reducing hospitalisations and deaths in its clinical trial of high-risk individuals by about 30%.\n\"The latest studies weren't good,\" Olivier Veran told BFM TV.\nMerck did not immediately respond to Reuters' request for comment.\nWhile vaccines are the main weapons against COVID-19 for governments, there are hopes Merck and Pfizer's experimental pills could be a game-changer in reducing the chances of dying or hospitalisation for those most at risk of severe illness.\nFrance had placed an early order for 50,000 doses of the drug molnupiravir developed by Merck and Ridgeback Biotherapeutics.\nThe cancellation would not incur a cost, Veran said.\nIn Italy, the office of the special commissioner for the COVID emergency said on Nov 18 it had received a mandate from the health ministry to buy 50,000 courses of Merck's pill and another 50,000 of Pfizer's one. \"The contract has not yet been finalised, but is in progress,\" a spokesperson for the commissioner told Reuters on Tuesday.\nItalian drug regulator Aifa's head Nicola Magrini told a Senate committee on Dec. 9 the two treatments could be available in Italy from the end of January.\nHowever, regardless of the availability of the drugs, there will be assessments of their use, two top government scientific advisers told Reuters.\n\"There must and will be an evaluation, independently of the assessments of regulatory bodies,\" Walter Ricciardi, top adviser of health minister Roberto Speranza, told Reuters.\nGermany has already bought Merck's antiviral treatment, health minister Karl Lauterbach told Reuters on Wednesday.\n\"This is a binding order,\" he said, adding Berlin was also in talks with Pfizer about buying its antiviral drug.\nThe European Medicines Agency is expected to decide whether to approve the Merck and Pfizer pills in the new year.\nPfizer's Paxlovid has shown near 90% efficacy in preventing COVID-19 hospitalisations and deaths in high-risk patients.\nFrance had purchased that drug instead, Veran said, without saying how many doses it had secured.\n\"France is lined up to get it before the end of January,\" Veran continued. It has not yet been decided whether the drug would be available over the counter in pharmacies, the minister said.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":691210367,"gmtCreate":1640193824058,"gmtModify":1640193824123,"author":{"id":"3580791049174344","authorId":"3580791049174344","name":"windz123","avatar":"https://static.tigerbbs.com/3f5527e97f3d63e3fa0d4f05b7f5230c","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3580791049174344","idStr":"3580791049174344"},"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691210367","repostId":2193019234,"repostType":4,"repost":{"id":"2193019234","kind":"news","pubTimestamp":1640181878,"share":"https://www.laohu8.com/m/news/2193019234?lang=&edition=full","pubTime":"2021-12-22 22:04","market":"us","language":"en","title":"France cancels order for Merck's COVID-19 antiviral drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2193019234","media":"Reuters","summary":"PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck & Co's COVID-19 antiviral drug fo","content":"<p>PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck &amp; Co's COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end of January, the health minister said on Wednesday.</p>\n<p>France is the first country to publicly say it has cancelled an order for the Merck treatment after the company released data in late November suggesting its drug was markedly less effective than previously thought, reducing hospitalisations and deaths in its clinical trial of high-risk individuals by about 30%.</p>\n<p>\"The latest studies weren't good,\" Olivier Veran told BFM TV.</p>\n<p>Merck did not immediately respond to Reuters' request for comment.</p>\n<p>While vaccines are the main weapons against COVID-19 for governments, there are hopes Merck and Pfizer's experimental pills could be a game-changer in reducing the chances of dying or hospitalisation for those most at risk of severe illness.</p>\n<p>France had placed an early order for 50,000 doses of the drug molnupiravir developed by Merck and Ridgeback Biotherapeutics.</p>\n<p>The cancellation would not incur a cost, Veran said.</p>\n<p>In Italy, the office of the special commissioner for the COVID emergency said on Nov 18 it had received a mandate from the health ministry to buy 50,000 courses of Merck's pill and another 50,000 of Pfizer's <a href=\"https://laohu8.com/S/AONE.U\">one</a>. \"The contract has not yet been finalised, but is in progress,\" a spokesperson for the commissioner told Reuters on Tuesday.</p>\n<p>Italian drug regulator Aifa's head Nicola Magrini told a Senate committee on Dec. 9 the two treatments could be available in Italy from the end of January.</p>\n<p>However, regardless of the availability of the drugs, there will be assessments of their use, two top government scientific advisers told Reuters.</p>\n<p>\"There must and will be an evaluation, independently of the assessments of regulatory bodies,\" Walter Ricciardi, top adviser of health minister Roberto Speranza, told Reuters.</p>\n<p>Germany has already bought Merck's antiviral treatment, health minister Karl Lauterbach told Reuters on Wednesday.</p>\n<p>\"This is a binding order,\" he said, adding Berlin was also in talks with Pfizer about buying its antiviral drug.</p>\n<p>The European Medicines Agency is expected to decide whether to approve the Merck and Pfizer pills in the new year.</p>\n<p>Pfizer's Paxlovid has shown near 90% efficacy in preventing COVID-19 hospitalisations and deaths in high-risk patients.</p>\n<p>France had purchased that drug instead, Veran said, without saying how many doses it had secured.</p>\n<p>\"France is lined up to get it before the end of January,\" Veran continued. It has not yet been decided whether the drug would be available over the counter in pharmacies, the minister said.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>France cancels order for Merck's COVID-19 antiviral drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFrance cancels order for Merck's COVID-19 antiviral drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-22 22:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/1-france-cancels-order-mercks-135238223.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck & Co's COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-france-cancels-order-mercks-135238223.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","BK4516":"特朗普概念","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","MRK":"默沙东","BK4007":"制药","PFE":"辉瑞"},"source_url":"https://finance.yahoo.com/news/1-france-cancels-order-mercks-135238223.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2193019234","content_text":"PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck & Co's COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end of January, the health minister said on Wednesday.\nFrance is the first country to publicly say it has cancelled an order for the Merck treatment after the company released data in late November suggesting its drug was markedly less effective than previously thought, reducing hospitalisations and deaths in its clinical trial of high-risk individuals by about 30%.\n\"The latest studies weren't good,\" Olivier Veran told BFM TV.\nMerck did not immediately respond to Reuters' request for comment.\nWhile vaccines are the main weapons against COVID-19 for governments, there are hopes Merck and Pfizer's experimental pills could be a game-changer in reducing the chances of dying or hospitalisation for those most at risk of severe illness.\nFrance had placed an early order for 50,000 doses of the drug molnupiravir developed by Merck and Ridgeback Biotherapeutics.\nThe cancellation would not incur a cost, Veran said.\nIn Italy, the office of the special commissioner for the COVID emergency said on Nov 18 it had received a mandate from the health ministry to buy 50,000 courses of Merck's pill and another 50,000 of Pfizer's one. \"The contract has not yet been finalised, but is in progress,\" a spokesperson for the commissioner told Reuters on Tuesday.\nItalian drug regulator Aifa's head Nicola Magrini told a Senate committee on Dec. 9 the two treatments could be available in Italy from the end of January.\nHowever, regardless of the availability of the drugs, there will be assessments of their use, two top government scientific advisers told Reuters.\n\"There must and will be an evaluation, independently of the assessments of regulatory bodies,\" Walter Ricciardi, top adviser of health minister Roberto Speranza, told Reuters.\nGermany has already bought Merck's antiviral treatment, health minister Karl Lauterbach told Reuters on Wednesday.\n\"This is a binding order,\" he said, adding Berlin was also in talks with Pfizer about buying its antiviral drug.\nThe European Medicines Agency is expected to decide whether to approve the Merck and Pfizer pills in the new year.\nPfizer's Paxlovid has shown near 90% efficacy in preventing COVID-19 hospitalisations and deaths in high-risk patients.\nFrance had purchased that drug instead, Veran said, without saying how many doses it had secured.\n\"France is lined up to get it before the end of January,\" Veran continued. It has not yet been decided whether the drug would be available over the counter in pharmacies, the minister said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":691678702,"gmtCreate":1640189099415,"gmtModify":1640189257857,"author":{"id":"3559267712174688","authorId":"3559267712174688","name":"kamy","avatar":"https://static.tigerbbs.com/88a23e0929fe2bdeac54d613c0b7197d","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3559267712174688","idStr":"3559267712174688"},"htmlText":"Gg","listText":"Gg","text":"Gg","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691678702","repostId":2193019234,"repostType":4,"repost":{"id":"2193019234","kind":"news","pubTimestamp":1640181878,"share":"https://www.laohu8.com/m/news/2193019234?lang=&edition=full","pubTime":"2021-12-22 22:04","market":"us","language":"en","title":"France cancels order for Merck's COVID-19 antiviral drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2193019234","media":"Reuters","summary":"PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck & Co's COVID-19 antiviral drug fo","content":"<p>PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck &amp; Co's COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end of January, the health minister said on Wednesday.</p>\n<p>France is the first country to publicly say it has cancelled an order for the Merck treatment after the company released data in late November suggesting its drug was markedly less effective than previously thought, reducing hospitalisations and deaths in its clinical trial of high-risk individuals by about 30%.</p>\n<p>\"The latest studies weren't good,\" Olivier Veran told BFM TV.</p>\n<p>Merck did not immediately respond to Reuters' request for comment.</p>\n<p>While vaccines are the main weapons against COVID-19 for governments, there are hopes Merck and Pfizer's experimental pills could be a game-changer in reducing the chances of dying or hospitalisation for those most at risk of severe illness.</p>\n<p>France had placed an early order for 50,000 doses of the drug molnupiravir developed by Merck and Ridgeback Biotherapeutics.</p>\n<p>The cancellation would not incur a cost, Veran said.</p>\n<p>In Italy, the office of the special commissioner for the COVID emergency said on Nov 18 it had received a mandate from the health ministry to buy 50,000 courses of Merck's pill and another 50,000 of Pfizer's <a href=\"https://laohu8.com/S/AONE.U\">one</a>. \"The contract has not yet been finalised, but is in progress,\" a spokesperson for the commissioner told Reuters on Tuesday.</p>\n<p>Italian drug regulator Aifa's head Nicola Magrini told a Senate committee on Dec. 9 the two treatments could be available in Italy from the end of January.</p>\n<p>However, regardless of the availability of the drugs, there will be assessments of their use, two top government scientific advisers told Reuters.</p>\n<p>\"There must and will be an evaluation, independently of the assessments of regulatory bodies,\" Walter Ricciardi, top adviser of health minister Roberto Speranza, told Reuters.</p>\n<p>Germany has already bought Merck's antiviral treatment, health minister Karl Lauterbach told Reuters on Wednesday.</p>\n<p>\"This is a binding order,\" he said, adding Berlin was also in talks with Pfizer about buying its antiviral drug.</p>\n<p>The European Medicines Agency is expected to decide whether to approve the Merck and Pfizer pills in the new year.</p>\n<p>Pfizer's Paxlovid has shown near 90% efficacy in preventing COVID-19 hospitalisations and deaths in high-risk patients.</p>\n<p>France had purchased that drug instead, Veran said, without saying how many doses it had secured.</p>\n<p>\"France is lined up to get it before the end of January,\" Veran continued. It has not yet been decided whether the drug would be available over the counter in pharmacies, the minister said.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>France cancels order for Merck's COVID-19 antiviral drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFrance cancels order for Merck's COVID-19 antiviral drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-22 22:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/1-france-cancels-order-mercks-135238223.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck & Co's COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-france-cancels-order-mercks-135238223.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","BK4516":"特朗普概念","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","MRK":"默沙东","BK4007":"制药","PFE":"辉瑞"},"source_url":"https://finance.yahoo.com/news/1-france-cancels-order-mercks-135238223.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2193019234","content_text":"PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck & Co's COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end of January, the health minister said on Wednesday.\nFrance is the first country to publicly say it has cancelled an order for the Merck treatment after the company released data in late November suggesting its drug was markedly less effective than previously thought, reducing hospitalisations and deaths in its clinical trial of high-risk individuals by about 30%.\n\"The latest studies weren't good,\" Olivier Veran told BFM TV.\nMerck did not immediately respond to Reuters' request for comment.\nWhile vaccines are the main weapons against COVID-19 for governments, there are hopes Merck and Pfizer's experimental pills could be a game-changer in reducing the chances of dying or hospitalisation for those most at risk of severe illness.\nFrance had placed an early order for 50,000 doses of the drug molnupiravir developed by Merck and Ridgeback Biotherapeutics.\nThe cancellation would not incur a cost, Veran said.\nIn Italy, the office of the special commissioner for the COVID emergency said on Nov 18 it had received a mandate from the health ministry to buy 50,000 courses of Merck's pill and another 50,000 of Pfizer's one. \"The contract has not yet been finalised, but is in progress,\" a spokesperson for the commissioner told Reuters on Tuesday.\nItalian drug regulator Aifa's head Nicola Magrini told a Senate committee on Dec. 9 the two treatments could be available in Italy from the end of January.\nHowever, regardless of the availability of the drugs, there will be assessments of their use, two top government scientific advisers told Reuters.\n\"There must and will be an evaluation, independently of the assessments of regulatory bodies,\" Walter Ricciardi, top adviser of health minister Roberto Speranza, told Reuters.\nGermany has already bought Merck's antiviral treatment, health minister Karl Lauterbach told Reuters on Wednesday.\n\"This is a binding order,\" he said, adding Berlin was also in talks with Pfizer about buying its antiviral drug.\nThe European Medicines Agency is expected to decide whether to approve the Merck and Pfizer pills in the new year.\nPfizer's Paxlovid has shown near 90% efficacy in preventing COVID-19 hospitalisations and deaths in high-risk patients.\nFrance had purchased that drug instead, Veran said, without saying how many doses it had secured.\n\"France is lined up to get it before the end of January,\" Veran continued. It has not yet been decided whether the drug would be available over the counter in pharmacies, the minister said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":691683875,"gmtCreate":1640183737368,"gmtModify":1640183761414,"author":{"id":"3577168442576973","authorId":"3577168442576973","name":"NeedMoneyPls","avatar":"https://static.tigerbbs.com/ae9445a785e57d1d8607eb2ae0dde618","vip":1,"crmLevel":5,"crmLevelSwitch":0,"authorIdStr":"3577168442576973","idStr":"3577168442576973"},"htmlText":"Wow I thought they said it's much more effective than Pfizer and Moderna. Wonder issit they got paid off so the other two can continue to earn money.&nbsp;","listText":"Wow I thought they said it's much more effective than Pfizer and Moderna. Wonder issit they got paid off so the other two can continue to earn money.&nbsp;","text":"Wow I thought they said it's much more effective than Pfizer and Moderna. Wonder issit they got paid off so the other two can continue to earn money.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/691683875","repostId":2193019234,"repostType":4,"repost":{"id":"2193019234","kind":"news","pubTimestamp":1640181878,"share":"https://www.laohu8.com/m/news/2193019234?lang=&edition=full","pubTime":"2021-12-22 22:04","market":"us","language":"en","title":"France cancels order for Merck's COVID-19 antiviral drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2193019234","media":"Reuters","summary":"PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck & Co's COVID-19 antiviral drug fo","content":"<p>PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck &amp; Co's COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end of January, the health minister said on Wednesday.</p>\n<p>France is the first country to publicly say it has cancelled an order for the Merck treatment after the company released data in late November suggesting its drug was markedly less effective than previously thought, reducing hospitalisations and deaths in its clinical trial of high-risk individuals by about 30%.</p>\n<p>\"The latest studies weren't good,\" Olivier Veran told BFM TV.</p>\n<p>Merck did not immediately respond to Reuters' request for comment.</p>\n<p>While vaccines are the main weapons against COVID-19 for governments, there are hopes Merck and Pfizer's experimental pills could be a game-changer in reducing the chances of dying or hospitalisation for those most at risk of severe illness.</p>\n<p>France had placed an early order for 50,000 doses of the drug molnupiravir developed by Merck and Ridgeback Biotherapeutics.</p>\n<p>The cancellation would not incur a cost, Veran said.</p>\n<p>In Italy, the office of the special commissioner for the COVID emergency said on Nov 18 it had received a mandate from the health ministry to buy 50,000 courses of Merck's pill and another 50,000 of Pfizer's <a href=\"https://laohu8.com/S/AONE.U\">one</a>. \"The contract has not yet been finalised, but is in progress,\" a spokesperson for the commissioner told Reuters on Tuesday.</p>\n<p>Italian drug regulator Aifa's head Nicola Magrini told a Senate committee on Dec. 9 the two treatments could be available in Italy from the end of January.</p>\n<p>However, regardless of the availability of the drugs, there will be assessments of their use, two top government scientific advisers told Reuters.</p>\n<p>\"There must and will be an evaluation, independently of the assessments of regulatory bodies,\" Walter Ricciardi, top adviser of health minister Roberto Speranza, told Reuters.</p>\n<p>Germany has already bought Merck's antiviral treatment, health minister Karl Lauterbach told Reuters on Wednesday.</p>\n<p>\"This is a binding order,\" he said, adding Berlin was also in talks with Pfizer about buying its antiviral drug.</p>\n<p>The European Medicines Agency is expected to decide whether to approve the Merck and Pfizer pills in the new year.</p>\n<p>Pfizer's Paxlovid has shown near 90% efficacy in preventing COVID-19 hospitalisations and deaths in high-risk patients.</p>\n<p>France had purchased that drug instead, Veran said, without saying how many doses it had secured.</p>\n<p>\"France is lined up to get it before the end of January,\" Veran continued. It has not yet been decided whether the drug would be available over the counter in pharmacies, the minister said.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>France cancels order for Merck's COVID-19 antiviral drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFrance cancels order for Merck's COVID-19 antiviral drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-22 22:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/1-france-cancels-order-mercks-135238223.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck & Co's COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-france-cancels-order-mercks-135238223.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","BK4516":"特朗普概念","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","MRK":"默沙东","BK4007":"制药","PFE":"辉瑞"},"source_url":"https://finance.yahoo.com/news/1-france-cancels-order-mercks-135238223.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2193019234","content_text":"PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck & Co's COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end of January, the health minister said on Wednesday.\nFrance is the first country to publicly say it has cancelled an order for the Merck treatment after the company released data in late November suggesting its drug was markedly less effective than previously thought, reducing hospitalisations and deaths in its clinical trial of high-risk individuals by about 30%.\n\"The latest studies weren't good,\" Olivier Veran told BFM TV.\nMerck did not immediately respond to Reuters' request for comment.\nWhile vaccines are the main weapons against COVID-19 for governments, there are hopes Merck and Pfizer's experimental pills could be a game-changer in reducing the chances of dying or hospitalisation for those most at risk of severe illness.\nFrance had placed an early order for 50,000 doses of the drug molnupiravir developed by Merck and Ridgeback Biotherapeutics.\nThe cancellation would not incur a cost, Veran said.\nIn Italy, the office of the special commissioner for the COVID emergency said on Nov 18 it had received a mandate from the health ministry to buy 50,000 courses of Merck's pill and another 50,000 of Pfizer's one. \"The contract has not yet been finalised, but is in progress,\" a spokesperson for the commissioner told Reuters on Tuesday.\nItalian drug regulator Aifa's head Nicola Magrini told a Senate committee on Dec. 9 the two treatments could be available in Italy from the end of January.\nHowever, regardless of the availability of the drugs, there will be assessments of their use, two top government scientific advisers told Reuters.\n\"There must and will be an evaluation, independently of the assessments of regulatory bodies,\" Walter Ricciardi, top adviser of health minister Roberto Speranza, told Reuters.\nGermany has already bought Merck's antiviral treatment, health minister Karl Lauterbach told Reuters on Wednesday.\n\"This is a binding order,\" he said, adding Berlin was also in talks with Pfizer about buying its antiviral drug.\nThe European Medicines Agency is expected to decide whether to approve the Merck and Pfizer pills in the new year.\nPfizer's Paxlovid has shown near 90% efficacy in preventing COVID-19 hospitalisations and deaths in high-risk patients.\nFrance had purchased that drug instead, Veran said, without saying how many doses it had secured.\n\"France is lined up to get it before the end of January,\" Veran continued. It has not yet been decided whether the drug would be available over the counter in pharmacies, the minister said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7079318,"gmtCreate":1640189203287,"gmtModify":1640189203391,"authorId":3582028884093480,"author":{"id":3582028884093480,"idStr":"3582028884093480","authorId":3582028884093480,"name":"慢的老人","avatar":"https://static.tigerbbs.com/d8809bb976396889eb133162af0901b8","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":691683875,"type":1,"supId":0,"prevId":0,"content":"I don't think any amount of money would be worth the reputational damage Merck would incur. It is more likely that Merck's drug was not tested extensively enough until now.","text":"I don't think any amount of money would be worth the reputational damage Merck would incur. It is more likely that Merck's drug was not tested extensively enough until now.","html":"I don't think any amount of money would be worth the reputational damage Merck would incur. It is more likely that Merck's drug was not tested extensively enough until now."},{"id":7078350,"gmtCreate":1640183898316,"gmtModify":1640183898351,"authorId":3573464435831021,"author":{"id":3573464435831021,"idStr":"3573464435831021","authorId":3573464435831021,"name":"halforc","avatar":"https://static.tigerbbs.com/231f5e9ec930fe4701bdb16cb6485b9a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":691683875,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"CN"},{"id":691689864,"gmtCreate":1640183646316,"gmtModify":1640183759638,"author":{"id":"3587089033625952","authorId":"3587089033625952","name":"BillyWu","avatar":"https://static.tigerbbs.com/fe9da814932e6e4dbcc103a2e82bd42f","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3587089033625952","idStr":"3587089033625952"},"htmlText":"Omg","listText":"Omg","text":"Omg","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691689864","repostId":2193019234,"repostType":4,"repost":{"id":"2193019234","kind":"news","pubTimestamp":1640181878,"share":"https://www.laohu8.com/m/news/2193019234?lang=&edition=full","pubTime":"2021-12-22 22:04","market":"us","language":"en","title":"France cancels order for Merck's COVID-19 antiviral drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2193019234","media":"Reuters","summary":"PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck & Co's COVID-19 antiviral drug fo","content":"<p>PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck &amp; Co's COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end of January, the health minister said on Wednesday.</p>\n<p>France is the first country to publicly say it has cancelled an order for the Merck treatment after the company released data in late November suggesting its drug was markedly less effective than previously thought, reducing hospitalisations and deaths in its clinical trial of high-risk individuals by about 30%.</p>\n<p>\"The latest studies weren't good,\" Olivier Veran told BFM TV.</p>\n<p>Merck did not immediately respond to Reuters' request for comment.</p>\n<p>While vaccines are the main weapons against COVID-19 for governments, there are hopes Merck and Pfizer's experimental pills could be a game-changer in reducing the chances of dying or hospitalisation for those most at risk of severe illness.</p>\n<p>France had placed an early order for 50,000 doses of the drug molnupiravir developed by Merck and Ridgeback Biotherapeutics.</p>\n<p>The cancellation would not incur a cost, Veran said.</p>\n<p>In Italy, the office of the special commissioner for the COVID emergency said on Nov 18 it had received a mandate from the health ministry to buy 50,000 courses of Merck's pill and another 50,000 of Pfizer's <a href=\"https://laohu8.com/S/AONE.U\">one</a>. \"The contract has not yet been finalised, but is in progress,\" a spokesperson for the commissioner told Reuters on Tuesday.</p>\n<p>Italian drug regulator Aifa's head Nicola Magrini told a Senate committee on Dec. 9 the two treatments could be available in Italy from the end of January.</p>\n<p>However, regardless of the availability of the drugs, there will be assessments of their use, two top government scientific advisers told Reuters.</p>\n<p>\"There must and will be an evaluation, independently of the assessments of regulatory bodies,\" Walter Ricciardi, top adviser of health minister Roberto Speranza, told Reuters.</p>\n<p>Germany has already bought Merck's antiviral treatment, health minister Karl Lauterbach told Reuters on Wednesday.</p>\n<p>\"This is a binding order,\" he said, adding Berlin was also in talks with Pfizer about buying its antiviral drug.</p>\n<p>The European Medicines Agency is expected to decide whether to approve the Merck and Pfizer pills in the new year.</p>\n<p>Pfizer's Paxlovid has shown near 90% efficacy in preventing COVID-19 hospitalisations and deaths in high-risk patients.</p>\n<p>France had purchased that drug instead, Veran said, without saying how many doses it had secured.</p>\n<p>\"France is lined up to get it before the end of January,\" Veran continued. It has not yet been decided whether the drug would be available over the counter in pharmacies, the minister said.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>France cancels order for Merck's COVID-19 antiviral drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFrance cancels order for Merck's COVID-19 antiviral drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-22 22:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/1-france-cancels-order-mercks-135238223.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck & Co's COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-france-cancels-order-mercks-135238223.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","BK4516":"特朗普概念","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","MRK":"默沙东","BK4007":"制药","PFE":"辉瑞"},"source_url":"https://finance.yahoo.com/news/1-france-cancels-order-mercks-135238223.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2193019234","content_text":"PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck & Co's COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end of January, the health minister said on Wednesday.\nFrance is the first country to publicly say it has cancelled an order for the Merck treatment after the company released data in late November suggesting its drug was markedly less effective than previously thought, reducing hospitalisations and deaths in its clinical trial of high-risk individuals by about 30%.\n\"The latest studies weren't good,\" Olivier Veran told BFM TV.\nMerck did not immediately respond to Reuters' request for comment.\nWhile vaccines are the main weapons against COVID-19 for governments, there are hopes Merck and Pfizer's experimental pills could be a game-changer in reducing the chances of dying or hospitalisation for those most at risk of severe illness.\nFrance had placed an early order for 50,000 doses of the drug molnupiravir developed by Merck and Ridgeback Biotherapeutics.\nThe cancellation would not incur a cost, Veran said.\nIn Italy, the office of the special commissioner for the COVID emergency said on Nov 18 it had received a mandate from the health ministry to buy 50,000 courses of Merck's pill and another 50,000 of Pfizer's one. \"The contract has not yet been finalised, but is in progress,\" a spokesperson for the commissioner told Reuters on Tuesday.\nItalian drug regulator Aifa's head Nicola Magrini told a Senate committee on Dec. 9 the two treatments could be available in Italy from the end of January.\nHowever, regardless of the availability of the drugs, there will be assessments of their use, two top government scientific advisers told Reuters.\n\"There must and will be an evaluation, independently of the assessments of regulatory bodies,\" Walter Ricciardi, top adviser of health minister Roberto Speranza, told Reuters.\nGermany has already bought Merck's antiviral treatment, health minister Karl Lauterbach told Reuters on Wednesday.\n\"This is a binding order,\" he said, adding Berlin was also in talks with Pfizer about buying its antiviral drug.\nThe European Medicines Agency is expected to decide whether to approve the Merck and Pfizer pills in the new year.\nPfizer's Paxlovid has shown near 90% efficacy in preventing COVID-19 hospitalisations and deaths in high-risk patients.\nFrance had purchased that drug instead, Veran said, without saying how many doses it had secured.\n\"France is lined up to get it before the end of January,\" Veran continued. It has not yet been decided whether the drug would be available over the counter in pharmacies, the minister said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":691689077,"gmtCreate":1640183609901,"gmtModify":1640183758903,"author":{"id":"3578711428062414","authorId":"3578711428062414","name":"StansenSG","avatar":"https://static.tigerbbs.com/103164c3fe87bb229920af5f907dbf60","vip":1,"crmLevel":6,"crmLevelSwitch":0,"authorIdStr":"3578711428062414","idStr":"3578711428062414"},"htmlText":"L","listText":"L","text":"L","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691689077","repostId":2193019234,"repostType":4,"repost":{"id":"2193019234","kind":"news","pubTimestamp":1640181878,"share":"https://www.laohu8.com/m/news/2193019234?lang=&edition=full","pubTime":"2021-12-22 22:04","market":"us","language":"en","title":"France cancels order for Merck's COVID-19 antiviral drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2193019234","media":"Reuters","summary":"PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck & Co's COVID-19 antiviral drug fo","content":"<p>PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck &amp; Co's COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end of January, the health minister said on Wednesday.</p>\n<p>France is the first country to publicly say it has cancelled an order for the Merck treatment after the company released data in late November suggesting its drug was markedly less effective than previously thought, reducing hospitalisations and deaths in its clinical trial of high-risk individuals by about 30%.</p>\n<p>\"The latest studies weren't good,\" Olivier Veran told BFM TV.</p>\n<p>Merck did not immediately respond to Reuters' request for comment.</p>\n<p>While vaccines are the main weapons against COVID-19 for governments, there are hopes Merck and Pfizer's experimental pills could be a game-changer in reducing the chances of dying or hospitalisation for those most at risk of severe illness.</p>\n<p>France had placed an early order for 50,000 doses of the drug molnupiravir developed by Merck and Ridgeback Biotherapeutics.</p>\n<p>The cancellation would not incur a cost, Veran said.</p>\n<p>In Italy, the office of the special commissioner for the COVID emergency said on Nov 18 it had received a mandate from the health ministry to buy 50,000 courses of Merck's pill and another 50,000 of Pfizer's <a href=\"https://laohu8.com/S/AONE.U\">one</a>. \"The contract has not yet been finalised, but is in progress,\" a spokesperson for the commissioner told Reuters on Tuesday.</p>\n<p>Italian drug regulator Aifa's head Nicola Magrini told a Senate committee on Dec. 9 the two treatments could be available in Italy from the end of January.</p>\n<p>However, regardless of the availability of the drugs, there will be assessments of their use, two top government scientific advisers told Reuters.</p>\n<p>\"There must and will be an evaluation, independently of the assessments of regulatory bodies,\" Walter Ricciardi, top adviser of health minister Roberto Speranza, told Reuters.</p>\n<p>Germany has already bought Merck's antiviral treatment, health minister Karl Lauterbach told Reuters on Wednesday.</p>\n<p>\"This is a binding order,\" he said, adding Berlin was also in talks with Pfizer about buying its antiviral drug.</p>\n<p>The European Medicines Agency is expected to decide whether to approve the Merck and Pfizer pills in the new year.</p>\n<p>Pfizer's Paxlovid has shown near 90% efficacy in preventing COVID-19 hospitalisations and deaths in high-risk patients.</p>\n<p>France had purchased that drug instead, Veran said, without saying how many doses it had secured.</p>\n<p>\"France is lined up to get it before the end of January,\" Veran continued. It has not yet been decided whether the drug would be available over the counter in pharmacies, the minister said.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>France cancels order for Merck's COVID-19 antiviral drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFrance cancels order for Merck's COVID-19 antiviral drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-22 22:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/1-france-cancels-order-mercks-135238223.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck & Co's COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-france-cancels-order-mercks-135238223.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","BK4516":"特朗普概念","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","MRK":"默沙东","BK4007":"制药","PFE":"辉瑞"},"source_url":"https://finance.yahoo.com/news/1-france-cancels-order-mercks-135238223.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2193019234","content_text":"PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck & Co's COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end of January, the health minister said on Wednesday.\nFrance is the first country to publicly say it has cancelled an order for the Merck treatment after the company released data in late November suggesting its drug was markedly less effective than previously thought, reducing hospitalisations and deaths in its clinical trial of high-risk individuals by about 30%.\n\"The latest studies weren't good,\" Olivier Veran told BFM TV.\nMerck did not immediately respond to Reuters' request for comment.\nWhile vaccines are the main weapons against COVID-19 for governments, there are hopes Merck and Pfizer's experimental pills could be a game-changer in reducing the chances of dying or hospitalisation for those most at risk of severe illness.\nFrance had placed an early order for 50,000 doses of the drug molnupiravir developed by Merck and Ridgeback Biotherapeutics.\nThe cancellation would not incur a cost, Veran said.\nIn Italy, the office of the special commissioner for the COVID emergency said on Nov 18 it had received a mandate from the health ministry to buy 50,000 courses of Merck's pill and another 50,000 of Pfizer's one. \"The contract has not yet been finalised, but is in progress,\" a spokesperson for the commissioner told Reuters on Tuesday.\nItalian drug regulator Aifa's head Nicola Magrini told a Senate committee on Dec. 9 the two treatments could be available in Italy from the end of January.\nHowever, regardless of the availability of the drugs, there will be assessments of their use, two top government scientific advisers told Reuters.\n\"There must and will be an evaluation, independently of the assessments of regulatory bodies,\" Walter Ricciardi, top adviser of health minister Roberto Speranza, told Reuters.\nGermany has already bought Merck's antiviral treatment, health minister Karl Lauterbach told Reuters on Wednesday.\n\"This is a binding order,\" he said, adding Berlin was also in talks with Pfizer about buying its antiviral drug.\nThe European Medicines Agency is expected to decide whether to approve the Merck and Pfizer pills in the new year.\nPfizer's Paxlovid has shown near 90% efficacy in preventing COVID-19 hospitalisations and deaths in high-risk patients.\nFrance had purchased that drug instead, Veran said, without saying how many doses it had secured.\n\"France is lined up to get it before the end of January,\" Veran continued. It has not yet been decided whether the drug would be available over the counter in pharmacies, the minister said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7078295,"gmtCreate":1640183614837,"gmtModify":1640183614915,"authorId":3578711428062414,"author":{"id":3578711428062414,"idStr":"3578711428062414","authorId":3578711428062414,"name":"StansenSG","avatar":"https://static.tigerbbs.com/103164c3fe87bb229920af5f907dbf60","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":691689077,"type":1,"supId":0,"prevId":0,"content":"<u>L</u>","text":"<u>L</u>","html":"<u>L</u>"}],"langContent":"CN"},{"id":691619412,"gmtCreate":1640182435454,"gmtModify":1640183732848,"author":{"id":"3573124081715681","authorId":"3573124081715681","name":"Lollmaorofl","avatar":"https://static.tigerbbs.com/d359f1ef78d2115b312a9a26806c1e40","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3573124081715681","idStr":"3573124081715681"},"htmlText":"Ah shit definitely not the best news for Merck...","listText":"Ah shit definitely not the best news for Merck...","text":"Ah shit definitely not the best news for Merck...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691619412","repostId":2193019234,"repostType":4,"repost":{"id":"2193019234","kind":"news","pubTimestamp":1640181878,"share":"https://www.laohu8.com/m/news/2193019234?lang=&edition=full","pubTime":"2021-12-22 22:04","market":"us","language":"en","title":"France cancels order for Merck's COVID-19 antiviral drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2193019234","media":"Reuters","summary":"PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck & Co's COVID-19 antiviral drug fo","content":"<p>PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck &amp; Co's COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end of January, the health minister said on Wednesday.</p>\n<p>France is the first country to publicly say it has cancelled an order for the Merck treatment after the company released data in late November suggesting its drug was markedly less effective than previously thought, reducing hospitalisations and deaths in its clinical trial of high-risk individuals by about 30%.</p>\n<p>\"The latest studies weren't good,\" Olivier Veran told BFM TV.</p>\n<p>Merck did not immediately respond to Reuters' request for comment.</p>\n<p>While vaccines are the main weapons against COVID-19 for governments, there are hopes Merck and Pfizer's experimental pills could be a game-changer in reducing the chances of dying or hospitalisation for those most at risk of severe illness.</p>\n<p>France had placed an early order for 50,000 doses of the drug molnupiravir developed by Merck and Ridgeback Biotherapeutics.</p>\n<p>The cancellation would not incur a cost, Veran said.</p>\n<p>In Italy, the office of the special commissioner for the COVID emergency said on Nov 18 it had received a mandate from the health ministry to buy 50,000 courses of Merck's pill and another 50,000 of Pfizer's <a href=\"https://laohu8.com/S/AONE.U\">one</a>. \"The contract has not yet been finalised, but is in progress,\" a spokesperson for the commissioner told Reuters on Tuesday.</p>\n<p>Italian drug regulator Aifa's head Nicola Magrini told a Senate committee on Dec. 9 the two treatments could be available in Italy from the end of January.</p>\n<p>However, regardless of the availability of the drugs, there will be assessments of their use, two top government scientific advisers told Reuters.</p>\n<p>\"There must and will be an evaluation, independently of the assessments of regulatory bodies,\" Walter Ricciardi, top adviser of health minister Roberto Speranza, told Reuters.</p>\n<p>Germany has already bought Merck's antiviral treatment, health minister Karl Lauterbach told Reuters on Wednesday.</p>\n<p>\"This is a binding order,\" he said, adding Berlin was also in talks with Pfizer about buying its antiviral drug.</p>\n<p>The European Medicines Agency is expected to decide whether to approve the Merck and Pfizer pills in the new year.</p>\n<p>Pfizer's Paxlovid has shown near 90% efficacy in preventing COVID-19 hospitalisations and deaths in high-risk patients.</p>\n<p>France had purchased that drug instead, Veran said, without saying how many doses it had secured.</p>\n<p>\"France is lined up to get it before the end of January,\" Veran continued. It has not yet been decided whether the drug would be available over the counter in pharmacies, the minister said.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>France cancels order for Merck's COVID-19 antiviral drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFrance cancels order for Merck's COVID-19 antiviral drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-22 22:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/1-france-cancels-order-mercks-135238223.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck & Co's COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-france-cancels-order-mercks-135238223.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","BK4516":"特朗普概念","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","MRK":"默沙东","BK4007":"制药","PFE":"辉瑞"},"source_url":"https://finance.yahoo.com/news/1-france-cancels-order-mercks-135238223.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2193019234","content_text":"PARIS, Dec 22 (Reuters) - France has cancelled its order for Merck & Co's COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end of January, the health minister said on Wednesday.\nFrance is the first country to publicly say it has cancelled an order for the Merck treatment after the company released data in late November suggesting its drug was markedly less effective than previously thought, reducing hospitalisations and deaths in its clinical trial of high-risk individuals by about 30%.\n\"The latest studies weren't good,\" Olivier Veran told BFM TV.\nMerck did not immediately respond to Reuters' request for comment.\nWhile vaccines are the main weapons against COVID-19 for governments, there are hopes Merck and Pfizer's experimental pills could be a game-changer in reducing the chances of dying or hospitalisation for those most at risk of severe illness.\nFrance had placed an early order for 50,000 doses of the drug molnupiravir developed by Merck and Ridgeback Biotherapeutics.\nThe cancellation would not incur a cost, Veran said.\nIn Italy, the office of the special commissioner for the COVID emergency said on Nov 18 it had received a mandate from the health ministry to buy 50,000 courses of Merck's pill and another 50,000 of Pfizer's one. \"The contract has not yet been finalised, but is in progress,\" a spokesperson for the commissioner told Reuters on Tuesday.\nItalian drug regulator Aifa's head Nicola Magrini told a Senate committee on Dec. 9 the two treatments could be available in Italy from the end of January.\nHowever, regardless of the availability of the drugs, there will be assessments of their use, two top government scientific advisers told Reuters.\n\"There must and will be an evaluation, independently of the assessments of regulatory bodies,\" Walter Ricciardi, top adviser of health minister Roberto Speranza, told Reuters.\nGermany has already bought Merck's antiviral treatment, health minister Karl Lauterbach told Reuters on Wednesday.\n\"This is a binding order,\" he said, adding Berlin was also in talks with Pfizer about buying its antiviral drug.\nThe European Medicines Agency is expected to decide whether to approve the Merck and Pfizer pills in the new year.\nPfizer's Paxlovid has shown near 90% efficacy in preventing COVID-19 hospitalisations and deaths in high-risk patients.\nFrance had purchased that drug instead, Veran said, without saying how many doses it had secured.\n\"France is lined up to get it before the end of January,\" Veran continued. It has not yet been decided whether the drug would be available over the counter in pharmacies, the minister said.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":53,"commentSize":7,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2193019234"}